what is known already: The seminal plasma fulfills critical functions for fertility by providing spermatozoa with a protective milieu, promoting their final maturation and modulating the immune responsiveness of the female reproductive tract. It is also considered to be a promising source of biomarkers of male infertility and/or pathologies of the male genital tract. study design, size, duration: This study combines proteomic analyses of normal seminal plasma together with transcriptomic gene expression profiling of human healthy tissues. materials, setting, methods: Non-liquefied seminal plasma proteins from a healthy donor were prefractionated using two sequential Proteominer TM libraries. Eight subproteome fractions were collected, trypsin digested and subjected to three successive mass spectrometry analyses for peptide characterization. The list of identified proteins was compared with and merged with other available data sets of the human seminal plasma proteome. The expression of corresponding genes was then investigated using tissue transcriptome profiles to determine where, along the male reproductive tract, these proteins were produced. Finally, tissue specificity of a selected subset of biomarker candidates was validated on human tissues. main results and the role of chance: We first performed a proteomic analysis of the human seminal plasma and identified 699 proteins. By comparing our protein list with other previous proteomic data sets, we found that 2545 unique proteins have been described so far in the human seminal plasma. We then profiled their expression at the gene level and identified 83 testis, 42 epididymis, 7 seminal vesicle and 17 prostate candidate protein markers. For a subset of testis-specific candidates, i.e. TKTL1, LDHC and PGK2, we further validated their germ cell expression and demonstrated that such markers could distinguish between semen from fertile and infertile men.
Introduction
Infertility is a common problem throughout the world. Approximately 15% of all couples encounter fertility problems during their reproductive lifetime and in about half of the cases the cause is of male origin (Bruckert, 1991; Juul et al., 1999) . Despite the possible deleterious role of lifestyle, environmental and/or genetic factors evoked on male reproduction, the etiologies of most infertility cases remain unknown. Routine semen analysis may indicate defective sperm production or diminished sperm motility as well as an abnormal sperm morphology resulting from a defective spermiogenesis. It may also reveal the absence of spermatozoa in semen, a situation termed azoospermia which concerns 8% of men with fertility problems (Rowe et al., 2000) . It is the consequence of either an obstructed or discontinuous male genital tract such as the bilateral agenesis of the vas deferens (obstructive azoospermia, OA) or a failure of the testis to initiate or maintain spermatogenesis due to endogenous or exogenous abnormalities (non-obstructive azoospermia, NOA).
The human seminal plasma is a complex biological fluid that originates from the testes (1 -2%), the epididymides (2 -4%), the seminal vesicles (65-75%), the prostate gland (25 -30%) and the bulbourethral or Cowper's glands (,1%). In addition to its obvious role in transporting male gametes, the seminal plasma provides a nutritive and protective milieu for spermatozoa. It is also actively involved in their final maturation as well as in modulating the immune responsiveness of the female reproductive tract (for reviews, see Robertson, 2005; Rodriguez-Martinez et al., 2011) . To fulfill its different functions, the seminal plasma is composed of a complex range of inorganic and organic constituents. For instance, it contains zinc that stabilizes the sperm chromatin, basic amines (e.g. putrescine, spermine, spermidine and cadaverine) that counteract the acidic environment of the vaginal canal, prostaglandins that are involved in suppressing an immune response in the female against the foreign semen and fructose that serves as the main energy source of sperm cells (for reviews, see Mann, 1954; Owen and Katz, 2005) .
Like most body fluids, seminal plasma also contains many proteins with different functions, some of them well known, some still obscure (for review, see Rodriguez-Martinez et al., 2011) , and has thus been the focus of several proteomic analyses (for review, see Duncan and Thompson, 2007) . These included systematic analyses of the normal seminal plasma itself (Fung et al., 2004; Pilch and Mann, 2006; Wang et al., 2009; Batruch et al., 2011) as well as targeted analyses of the prostasome content (Utleg et al., 2003; Poliakov et al., 2009) , the expressed prostatic secretions (Drake et al., 2009) or the epididymosome content (Thimon et al., 2008) . Taken together, these studies considerably extended the repertoire of human seminal plasma proteins. However, only little is known about the respective contribution of each participating organ to this biofluid. The fact that secretions and associated proteins from different glands are combined only at the time of ejaculation is actually non-trivial. For instance, the mixing together of these various glandular fractions leads to a spontaneous coagulation of the fresh ejaculate in the rear vaginal cavity. This coagulum, which mainly consists of semenogelin-1 and semenogelin-2 (SEMG1 and SEMG2, respectively) from the seminal vesicles, will liquefy after 15-25 min due to the proteolytic activity of some prostatic enzymes such as the prostate specific antigen which allows a progressive release of motile spermatozoa (for review, see de Lamirande, 2007) . Therefore, the identification of the tissue of origin of the seminal plasma constituents is important to fully understand how these proteins may interact together to achieve their function(s). It is also likely to allow the identification of biological markers for organs participating in the semen secretion.
In the current study, we aimed at deciphering further the human seminal plasma proteome by predicting where along the male reproductive tract the seminal plasma proteins were produced. We also validated the specificity of several germ cell markers identified in this biofluid, i.e. transketolase-like protein 1 (TKTL1), phosphoglycerate kinase 2 (PGK2) and L-lactate dehydrogenase C chain (LDHC), and propose that such markers may help clinicians to better diagnose causes of male infertility.
Methods

Materials
The solid-phase combinatorial peptide Library-1 (ProteoMiner TM ) and carboxylated version (Library-2) were both from Bio-Rad Laboratories (Hercules, CA, USA) as were materials for electrophoresis such as plates and reagents. Sequencing grade trypsin was from Promega (Madison, WI, USA). All other chemicals were from Sigma-Aldrich (Saint Quentin Fallavier, France).
Human seminal plasma collection
Proteomic analysis was conducted on pooled ejaculates from a single healthy donor, which were processed as described elsewhere (Pilch and Mann, 2006) . Briefly, fresh ejaculates were recovered on ice and immediately centrifuged at 14 000 g for 5 min at 48C. The supernatants were supplemented with protease inhibitors (Complete TM Protease Inhibitor Cocktail; Roche Applied Science) prior to ultracentrifugation at 105 000 g for 45 min at 48C. For each ejaculate, the clear supernatant resulting from ultracentrifugation was stored at 2808C until use. Protein concentration was finally determined in pooled ejaculates using the bicinchoninic acid (BCA) protein assay (Sigma-Aldrich).
For western blot analyses, seminal plasmas from patients undergoing infertility check-up were collected following the current World Health Organization guidelines (Rowe et al., 2000) . After liquefaction at room temperature for 30 min, seminal plasmas were centrifuged at 14 000g for 10 min at 48C, complemented with anti-proteases (Complete TM Protease Inhibitor Cocktail; Roche Applied Science) and ultracentrifuged at 105 000g at 48C for 60 min. The protein concentration was then determined using the BCA protein assay (Sigma-Aldrich) prior storage at 2808C.
Combinatorial peptide ligand library fractionation of seminal plasma proteins
The seminal plasma (472 mg proteins) was loaded onto a column containing 1 ml of NH 2 -Library (Fractions E). The column effluent was continuously injected in a second column packed with COOH-Library (Fractions S). The columns connected in series were then washed with a phosphate-buffered saline until UV baseline of the effluent of the second column was reached. After the wash, each individual column was subjected to four distinct elutions (Fractions 1 -4) . The eight eluates (Fractions E1-E4 and S1 -S4) were immediately neutralized, desalted by dialysis at 48C against a 10-mM ammonium carbonate solution (cut-off of dialysis membrane was 1000 Da) and then lyophilized. For a more detailed protocol, see the Supplementary data.
Nano-LC-MS/MS analysis of human seminal plasma proteins
Eluates from the Proteominer TM fractionation were resuspended in ammonium bicarbonate to adjust the sample concentration to 1 mg/ml, then 5 mg of proteins of each fraction were reduced and alkylated. Proteins were digested using modified trypsin (Promega, Madison, WI, USA). Finally, the peptide mixtures were analyzed by nano-LC-MS/MS on a LTQ-Orbitrap XL mass spectrometer (Thermo Fisher Scientific, Bremen, Germany). For a full description of the analytical parameters, see the Supplementary data.
Data processing and analysis
The Proteome Discoverer software (version 1.2; Thermo Fisher Scientific) with the SEQUESTw and Mascot search algorithms was used for protein identification. MS/MS spectra were searched against UniProt human Database (Release 2011_05; 20 239 sequences; 11 284 379 residues) for peptide characterization and protein identification. The Proteome Discoverer software was also used to generate lists of identified peptides in order to exclude them for subsequent LC-MS/MS analyses. A total of three acquisitions per sample were performed using this strategy. For the third analysis, results files from the first two runs were combined in the Proteome Discoverer software to generate a second exclusion list that contained peptides identified from the first and second acquisitions. For a full description of analytical parameters, see the Supplementary data.
Mapping of protein identifiers from other published data sets
Protein identifiers (IDs) from previous studies (GI numbers; Fung et al., 2004; Thimon et al., 2008) ; UniProt Entry names (Utleg et al., 2003; Drake et al., 2009) ; UniProt Accession numbers (Pilch and Mann, 2006; Poliakov et al., 2009) ; International Protein Index (IPI) numbers (Wang et al., 2009; Batruch et al., 2011) were retrieved and converted into current UniProt Accession numbers using the UniProt Batch retrieval and ID mapping modules (http://www.uniprot.org; release 2011_12). All UniProt accession numbers were further linked to EntrezGene IDs that were mapped to corresponding probe sets on HG-U133 Plus 2.0 GeneChipw arrays using the Affymetrix CSV file (http://www.affymetrix .com/index.affx; release 32; 9 June 2011). Combined data from the nine data sets are available in the Supplementary data, File S1.
Microarray tissue profiling experiments
Human seminal vesicles data set Normal seminal vesicles were obtained at the Rennes University Hospital from patients who underwent radical prostatectomy. The protocol was approved by the local ethics committee of Rennes, and informed consent was obtained from the donors. Total RNAs were extracted using Trizol reagent (Invitrogen, Cergy Pontoise, France), purified with phenol -chloroform and cleaned-up using RNeasy Total RNA Isolation Kit (Qiagen, Courtaboeuf, France). Total RNAs (500 ng) were used as templates in an in vitro transcription reaction using the GeneChipw 3 ′ IVT Express Kit (Affymetrix, Santa Clara, CA, USA) according to the manufacturer's instructions. Purified labeled cRNAs (20 mg) were fragmented and hybridized to HG-U133 Plus 2.0 GeneChipw arrays (Affymetrix). GeneChips were then washed using a GeneChipw Fluidics Station 450 (Affymetrix) and stained according to the manufacturer's instructions. Corresponding CEL files are available on the NCBI Gene Expression Omnibus public repository (GSE17340).
Normalization and filtration procedures
CEL files corresponding to human prostates (GSE7307), epididymides (GSE7808; Thimon et al., 2007) and testicular samples (E-TABM-130; Chalmel et al., 2007) were downloaded from the NCBI GEO and from the EBI ArrayExpress public repositories. They were uploaded into the AMEN software (http://sourceforge.net/projects/amen/; Chalmel and Primig, 2008) together with our seminal vesicle data set and submitted to the RMA normalization procedure (Irizarry et al., 2003) . Transcripts detected in a single tissue were selected as follows: signal intensities had to be above the median value (4.94531056811573) in that tissue and under this value in all other tissues. A fold change of ≥3 between the given sample and all other tissues was further required. Selected probesets were finally submitted to a statistical filtration (Limma statistical test, false discovery rate of ,1%; Wettenhall and Smyth, 2004) Gene ontology term analysis UniProt accession numbers corresponding to all proteins identified within the seminal plasma were compared with the Human IPI proteome file to search for over-and under-represented functional annotation terms using the AMEN software. Similarly, genes identified as being expressed in a tissue specific way were compared with those of the entire microarray. For a full description of methodology, see the Supplementary data.
Validation experiment
Western blot analyses and/or immunohistochemistry experiments were performed as previously described (Com et al., 2006) . The primary antibodies used for western blots were the mouse monoclonal anti-TKTL1 antibody ( 
Results
Fractionation and nano-LC-MS/MS analysis of the human seminal plasma
The large dynamic range of protein species present in biological fluids often prevents access to low-copy-number proteins in proteomic studies. To access such proteins, we used the Proteominer TM library technology to prefractionate seminal plasma prior to beginning proteome analysis. Non-liquefied seminal plasma was first loaded onto two different peptide libraries. The retained proteins were then subjected to four different elutions, which generated eight subproteome fractions. These fractions, as well as the initial crude sample and the final flow through, were then trypsin digested and injected into a LTQ-Orbitrap TM XL mass spectrometer to characterize the peptides by nano-LC-MS/MS analysis. Whereas 127 different proteins were successfully identified in the raw human seminal plasma, between 60 and 258 proteins were characterized in the Proteominer TM fractions (Fig. 1A, Injection 1) . Interestingly, between only 60 and 121 proteins were identified in the S1 -S4 fractions, whereas between 112 and 258 proteins were identified in the E1 -E4 fractions, which corresponded to 103% more protein identifications (Fraction E4) than in the raw seminal plasma (Fig. 1A, Injection 1) . Thus, nano-LC-MS/MS analysis of the 8 Proteominer TM fractions together with the flow-through allowed the characterization of 520 unique proteins.
Additionally, we developed an exclusion list strategy for nano-LC-MS/ MS analysis with the aim of increasing peptide identification. Following a first injection and identification step, fractions were injected a second time into the instrument and an Xcalibur TM method file was adjusted to focus on peptides that had not been characterized previously. This allowed us to identify between 11% (flow-through) and 58% (Fraction E1) more proteins, respectively (Fig. 1A, Injection 2) . Finally a third nano-LC-MS/MS analysis, using an exclusion list that combined peptides characterized in the two first injections, allowed up to 26% more proteins (Fraction S1) to be identified (Fig. 1A, Injection 3) . Overall, 99 and 50 additional proteins were thus identified during the second and third nanoLC MS/MS analyses, respectively.
The combination of Proteominer TM prefractionation on the two peptide libraries and our iterative exclusion list strategy brought the total number of proteins identified in this study to 669 (Fig. 1B) .
Unraveling the human seminal plasma proteome
We next aimed at building a reference map of the human seminal plasma proteome by integrating into our data set results from previous relevant proteomic studies of this fluid. Protein IDs from each data set were first retrieved and converted into current UniProt accession numbers in order to manage redundancy. We next compared these data sets and found that overall, 2545 unique proteins have been described so far in the human seminal plasma (Fig. 1B) . These proteins correspond to 2401 non-redundant genes (Fig. 1B) and include 1051 proteins that have been identified in at least two distinct studies and 1494 proteins that have been identified in only one study (Supplementary data, File S1). We found the entire data set to be enriched in functions that are consistent with what we know or could expect from this biological fluid (Fig. 1C) . The majority of these proteins are indeed involved in protein binding (1277) or catalytic activity (1000) and notably includes hydrolases (556), peptidases (165) as well as peptidase inhibitors (70). Most of them are either extracellular (540) or cytoplasmic proteins (1494) and the latter are mainly found in vesicles and the endomembrane system (410) or in the cytoskeleton (264). Conversely, the human seminal plasma proteome shows depletion in nucleic acid-binding proteins, transcription regulators and membrane receptors and channels, which is further evidenced at the cellular component level by the low representation of nuclear as well as transmembrane proteins (Fig. 1C) . This compiled data set is accessible through Supplementary data, File S1.
Identification of biological markers of the human male reproductive tract
The human seminal plasma is mainly composed of secretions from the seminal vesicles, the prostate, the epididymides and the testes. To decipher the respective contribution of each organ to the seminal plasma content, we performed a tissue-profiling analysis using publicly available gene expression data sets (testis, epididymis and prostate) and one data set that we generated for this study (seminal vesicle, GSE17340). The HG-U133 Plus 2.0 GeneChipw arrays notably contain 5445 probe sets that allow the investigation of gene expression for 2328 seminal plasma proteins (Fig. 1B, Supplementary data , File S1). We first identified genes that are specifically expressed (see the section Materials and methods for expression cut-offs) in each organ: the testis (1980 genes), the epididymis (389 genes), the seminal vesicle (37 genes) and the prostate (54 genes) (Supplementary  data, Fig. S1A ). The relevance of these genes was confirmed by highlighting enriched functions that are consistent with the biology of the respective organs, e.g. 'spermatogenesis' or 'meiosis' for the testis or 'prostate gland development' for the prostate (Supplementary data, Fig. S1B ). We then focused on subsets of genes that were expressed in a tissue-specific manner and for which the corresponding gene product had also been identified in the human seminal plasma. We thus highlighted 83 testis, 42 epididymis, 7 seminal vesicle and 17 prostate proteins that represent potential markers in the human seminal plasma (Fig. 2, Supplementary data, File S2 ).
Validation of markers of male genital tract organs
Several of the proteins identified above are already known to be specific products of one of the four tissues investigated, e.g. SEMG1 and SEMG2 for the seminal vesicles, and FOLH1 and TGM4 for the prostate. In order to validate the biomarker status of some of our candidate proteins, we performed western blot analyses and/or immunohistochemistry using the few commercially available antibodies. TKTL1, LDHC and PGK2 were consistently detected in testicular extracts and in normal seminal plasma only (Fig. 3A) . Immunohistochemical studies further confirmed the testis-specific expression of TKTL1, LDHC and PGK2. TKTL1 was found expressed throughout germ cell development, with spermatogonia exhibiting the strongest labeling. LDHC was expressed in both meiotic spermatocytes and post-meiotic spermatids, whereas PGK2 was specifically observed in elongated spermatids (Fig. 3B) . In the head segment of the epididymis, PGK2 and to a lesser extent LDHC immunoreactivities were present in epithelial cells, known to be involved in protein reabsorption (Fig. 3B) . Of note is that while one could expect to observe labeled epididymal spermatozoa (which are known to express PGK2 and LDHC), this was not true here because of extensive washes performed prior to tissue fixation and embedding. On the other hand, the expression of the epididymis-specific protein S100A7 was validated: whereas no staining was observed in the testis, the seminal vesicle, the prostate and the head of the epididymis, a signal was detected in the body, and reached highest levels in the epithelial cells of the tail (Fig. 3B) . Finally, we assessed the presence of potential testicular germline markers in seminal plasma using sperm samples from fertile donors and from patients exhibiting various conditions (Fig. 3C) . Whereas TKTL1, LDHC and PGK2 were consistently (Pilch and Mann, 2006; Poliakov et al., 2009 ) and IPI numbers (Wang et al., 2009; Batruch et al., 2011) ) were retrieved and converted into UniProt accession numbers using the UniProt batch retrieval and ID mapping modules (http://www.uniprot.org; release 2011_12). UniProt accession numbers were finally linked to EntrezGene IDs and associated Probe sets from the HG-U133 Plus 2.0 GeneChipw arrays (Affymetrix) in order to perform the tissue-profiling analysis. (C) Functional mining of the human seminal plasma proteome. All proteins identified in the human seminal plasma proteome and their associated gene ontology (GO) terms were compared with those of the entire human proteome data set. 'Molecular function' and 'cellular component'-enriched or -depleted GO terms were identified using the Fisher exact probability test. Only GO terms with a P-value of ≤10 25 and for which the number of proteins bearing the annotation term was ≥30 were considered as statistically enriched. To avoid redundancy between closely related terms, we applied an ontology-specific information rate of ≥0.4 (Chalmel and Primig, 2008) . Rectangles indicate the observed (left) and expected (right) numbers of proteins bearing a specific GO term, whereas the number of proteins exhibiting this GO term in the entire human proteome is given next to the rectangle. Statistical enrichment (red) or depletion (blue) is indicated according to the scale bar.
detected in normal seminal plasmas, these proteins were either undetectable or barely detectable in seminal plasmas from patients with NOA, OA and vasectomized men (Fig. 3C) .
Discussion
Deciphering the seminal plasma proteome is important for gaining new insights into the male gamete biology. Indeed, proteins identified thus far in the seminal plasma cover a large array of functions, ranging from energy production or immune response, to cell recognition (for reviews, see Robertson, 2005 ; Rodriguez-Martinez et al., 2011).
However, only few are unambiguously linked to (in)fertility. With the goal of constructing a comprehensive annotation of this biological fluid, we conducted an in-depth proteomic analysis of the human seminal plasma and identified a total of over 2500 gene products either directly or by inference from previously published works. We also designed an integrative genomics approach to coalesce the proteomic data together with the transcriptomic profiles of the organs involved in the production of this biofluid. Using this innovative method, we identified multiple potential organ marker proteins that could be used to create molecular signatures of normal seminal plasma and serve as diagnostic tool for male reproductive disorders. In this study, we focused first on the proteomic analysis of the human seminal plasma. We combined sample pre-fractionation using peptide ligand library columns with subsequent shotgun nano-LC-MS/MS analysis of the tryptic peptides corresponding to each elution fraction and identified 669 proteins. Ligand libraries have been shown to be a key technology for capturing low-abundance proteins of the so-called 'deep' proteome (for reviews, see Righetti et al., 2006; Righetti and Boschetti, 2008 ; Boschetti and Righetti, Figure 3 Validation of candidate markers of the urogenital tract. (A) Western blot analysis of TKTL1, LDHC and PGK2 in human tissues. Protein extracts (20 mg) from human testis (T), head, body and tail of the epididymis (EpH, EpB and EpT, respectively), seminal vesicle (SV), prostate (P) and normal seminal plasma (SP) were separated on 12% polyacrylamide gels, electrotransferred onto PVDF membranes and probed with specific antibodies. TKTL1, LDHC and PGK2 were detected only in the testicular protein extract and in normal seminal plasma. (B) Immunolocalization of TKTL1, LDHC, PGK2 and S100A7 along the male urogenital tract. Tissues were fixed by immersion in a formalin fixative and embedded in paraffin. Sections (5 mm) were dewaxed, rehydrated and incubated with antibodies against TKTL1, LDHC, PGK2 or S100A7. Complexes were revealed using a strepavidin-peroxidase amplification combination and sections were counterstained with Masson hematoxylin. TKTL1, LDHC and PGK2 immunoreactivities were detected only in the testis. TKTL1 immunostaining was present in all germ cells, with spermatogonia (arrowheads) exhibiting the strongest staining. LDHC was detected in meiotic spermatocytes (arrowheads) and post-meiotic spermatids (arrows), and PGK2 was detected only in post-meiotic spermatids (arrows). Some residual immunostaining for PGK2 and to a lesser extent for LDHC was observed in epithelial cells in the epididymis head sections (arrowheads). S100A7 was detected only in the body and the tail of the epididymis (arrowheads). Scale bars: 100 mm. (C) Screening for the testicular germline markers TKTL1, LDHC and PGK2 in the seminal plasma of normal and infertile donors. Seminal plasmas (50 mg protein), from fertile donors (lanes 1 -5 and 10 -13), from patients with NOA (lanes 7, 8, 14, 15 and 18) or OA (lanes 9 and 16) or from vasectomized men (lanes 6, 17), were separated on 12% polyacrylamide gels, electrotransferred onto PVDF membranes and probed with specific antibodies. TKTL1, LDHC and PGK2 proteins were all detected in seminal plasmas from fertile donors only.
2009). This approach has notably been used to prefractionate biological fluids such as the urine (Castagna et al., 2005) , plasma (Sennels et al., 2007) and cerebrospinal fluid (Mouton-Barbosa et al., 2010) in which the overwhelming signals produced by a few dominant proteins hamper accessing the proteins present at very low concentrations. Although the success of decreasing the dynamic range of protein concentrations with the Proteominer TM library is difficult to evaluate in the present study, the sequential elution of proteins bound to the library columns clearly produced enriched fractions that allowed four times more proteins to be identified. Additionally, it was important to optimize the number of proteins in the injected samples that could be identified by mass spectrometry. This is why we tested a new nano-LC-MS/MS strategy to investigate the poorly represented species in each elution fraction. This involved re-injecting the sample for a second analysis by LC-MS/MS in which the previously identified peptides were excluded. Such an approach to performing a thorough sampling of complex protein mixtures was first described by Rudomin et al. (2009) . In the present study, this procedure was performed twice for a total of three LC-MS/MS acquisitions per sample. This resulted in the identification of .50% additional proteins in some individual fractions and in reinforcing the identification of 35% of proteins initially identified through a single peptide characterization.
Once our analysis of the human seminal plasma proteome was completed, the list of identified proteins was merged with the existing data sets obtained from published studies (Utleg et al., 2003; Fung et al., 2004; Pilch and Mann, 2006; Thimon et al., 2008; Drake et al., 2009; Poliakov et al., 2009; Wang et al., 2009; Batruch et al., 2011) . Some of these studies were published several years ago with often MS data not publicly available, which prevented us from performing protein identification against current databases and, most importantly, according to current guidelines. Instead, we had to convert and update all protein IDs provided in these studies into current Uniprot IDs prior to comparing them. We then found that .2500 non-redundant proteins were identified in the human seminal plasma so far. The different data sets only partially overlapped. A first explanation could be that differences in sample preparation or origin (i.e. liquefied versus non-liquefied plasma seminal, prostasomes, epididymosomes) and in fractionation methods employed prior to analysis (i.e. 1D gel, 2D gel, ligand libraries) resulted in different protein enrichments. A second explanation would be that only very abundant seminal plasma proteins could be consistently identified across studies, while the identification of low-abundance ones would be more random. This latter hypothesis was confirmed when we used the number of characterized peptides as a reflection of protein abundance and found that proteins retrieved in multiple studies had been identified through a much higher number of peptides than those identified in only a single study (data not shown). While a small complement of low-abundance proteins certainly remains to be identified, the present data set is probably close to the complete seminal plasma proteome and constitutes a fundamental base to gain insights into this biofluid.
While the deciphering of the human seminal plasma proteome has greatly progressed over the past decade, still too little is known regarding the respective contribution of each organ to this biofluid. This lack of knowledge dramatically impairs our full understanding of how these proteins may interact together at the time of ejaculation and achieve their function(s) once mixed together. In order to predict the tissue origin for each of these proteins, we integrated proteomic data sets together with transcriptome gene expression data for each of the organs involved in the biofluid production. We aimed at demonstrating that it was possible with such an integrative approach to highlight proteins of interest without performing the so-called 'differential studies' generally employed to compare normal and pathological biofluids for biomarker identification projects. Through our analysis, we identified numerous proteins whose gene expression was restricted to the testes, epididymides, seminal vesicles and prostate. The monitoring of such proteins in the seminal plasma would potentially offer a non-invasive diagnosis tool for various reproductive disorders associated with each of these organs. As an example, the gene expression levels of at least three of the prostate markers identified in the present study (i.e. ALOX15B, DSC3 and TGM4) appear to be down-regulated in patients exhibiting benign or aggressive prostate tumors (Varambally et al., 2005) . Thus, the expected decreased concentration of the corresponding proteins in the seminal plasma may possibly help early diagnosis of such pathologies.
In men with NOA, one or several invasive testicular biopsies are proposed to the patient for eventually recovering a few mature germ cells and entering an intracytoplasmic sperm injection program. These invasive biopsies may impair future spermatogenesis or induce testicular atrophy and only lead to sperm cell recovery in 50% of cases (for review, see Ishikawa, 2012) . Several indicators have been proposed to be potential indirect markers for the presence of spermatozoa in the testis. These include examination parameters (i.e. 2D:4D finger length ratio; Auger and Eustache, 2011) and proteins secreted by Sertoli cells such as inhibin A and B or AMH. However, none of these factors could be reliably used to predict successful biopsy outcomes (Anawalt et al., 1996; Illingworth et al., 1996; Anderson et al., 1998; Fenichel et al., 1999; von Eckardstein et al., 1999; Brugo-Olmedo et al., 2001; El Garem et al., 2002; Guthauser et al., 2002; Vernaeve et al., 2002; and for review, see Carpi et al., 2009) . To date the only valuable method for answering whether or not spermatozoa can be found in the testes of NOA patients is actually the surgery with testis biopsy itself. This crucially calls for the discovery and validation of specific seminal plasma biomarkers that are absolutely required by clinicians and will help in predicting spermpositive testicular biopsies. From our protein candidate list, we notably found 83 seminal plasma proteins for which the expression of the corresponding genes was only detected in the testis. Importantly, most of these genes were specifically expressed in the germline, as evidenced by their high expression levels in isolated spermatocyte and spermatid samples. When investigated by immunohistochemistry, some of the corresponding proteins appeared to be expressed in the testis throughout germ cell maturation (i.e. TKTL1), whereas others were restricted to meiotic and/or post-meiotic germ cells (i.e. LDHC and PGK2). Interestingly, the presence/absence of a combination of such germ cell protein markers in the seminal plasma could be correlated with the status of spermatogenesis in NOA patients. Ideally, the seminal plasma of a Sertoli-Cell-Only syndrome patient would be negative for all three markers, patients with maturation arrests at either the spermatogonia or spermatocyte stages would be positive for TKTL1 or TKTL1 and LDHC, respectively, while patients with complete spermatogenesis would be positive for TKTL1, LDHC and PGK2. Additionally, since both PGK2 and LDHC are required for sperm mobility and male fertility (Odet et al., 2008; Danshina et al., 2010) , the detection of these proteins in the human seminal plasma would guarantee not only the retrieval of testicular spermatozoa, but also their good quality. Using western blots, we clearly detected these three germ cell markers in normal seminal plasmas and were thus able to successfully distinguish those from seminal plasmas devoid of spermatozoa. Routinely, however, the measurement of germ cell markers in the seminal plasma may appear impractical. Indeed, in some pathological NOA situations only a few nests of residual spermatogenesis can be present in various areas of the testes. As a consequence the expected germ cell protein markers could be found at very low amounts in the seminal plasma. Therefore, the development of a more sensitive diagnostic antibody array (Fertichip TM ) for measuring several of those identified germ cell markers in normal and pathological seminal plasmas using specific monoclonal antibodies is ongoing in our laboratory.
Recently, two proteomic studies with a similar aim as ours were conducted by the same group (Batruch et al., 2011; Drabovich et al., 2011) . In the first one, Batruch et al. (2011) directly compared the seminal plasma proteome of fertile donors with that of vasectomized men. The authors assumed that proteins specific to the seminal plasmas of fertile donors originate from the testis and/or the epididymis, which was partially confirmed by database searching and literature mining. According to our tissue profiling experiment, the genes corresponding to 15 of the 32 potential protein markers identified by Batruch et al. (2011) were indeed found to be expressed in only one or both organs (data not shown). Importantly, the remaining ones were also expressed in other tissues (e.g. the seminal vesicles and/or the prostate) illustrating that the lack of a protein being identified in a sample is not always a convincing indication that the protein is not expressed. In a more recent follow-up study, Drabovich et al. (2011) used their biomarker candidate list to develop a multiplex assay based on the selected reaction monitoring technology with the objective of discriminating OA from NOA patients. This study was rather convincing, as their approach appeared efficient and robust to distinguish normal seminal plasmas from that of NOA or vasectomized men. Even more promising were 11 markers that allowed the discrimination of NOA from vasectomized men and could potentially distinguish between different NOA patients (Drabovich et al., 2011) . However, we could demonstrate from our transcriptomic data set that these 11 markers are expressed in the epididymis but not, or only at baseline levels, in the testis (data not shown). As a consequence, these 11 proteins can indeed distinguish NOA from vasectomized men, not because of the absence of spermatozoa in vasectomized samples, but because of the absence of epididymal secretions. Their use for predicting the status of spermatogenesis in NOA patients may thus be questionable.
In the present study, we used an integrative genomics approach involving in-depth proteomic characterization and bioinformatic mining of the human seminal plasma together with transcriptomic analysis to predict tissue origin of the protein constituents of this biofluid. This concept study led to the identification of several biomarkers specific to each of the organs involved in the seminal plasma production, including specific proteins of post-meiotic germ cells whose presence in seminal plasmas might be monitored by clinicians to better diagnose infertile patients, in particular those with NOA.
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